- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ZEO SCIENTIFIX Aktie jetzt für 0€ handeln | |||||
| 09.07. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.07. | Zeo ScientifiX, Inc.: ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida | 426 | ACCESS Newswire | ZEO Launches New Website and Agency Partnerships to Address Expected Biologics Market Demand Following Florida's New Stem Cell Law FORT LAUDERDALE, FL / ACCESS Newswire / July 9, 2025 / ZEO ScientifiX... ► Artikel lesen | |
| 24.06. | Zeo ScientifiX, Inc.: ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation | 207 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / June 24, 2025 / ?ZEO ScientifiX, Inc.?("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company pioneering the research and development... ► Artikel lesen | |
| 24.06. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 16.05. | Zeo ScientifiX, Inc. - S-1/A, General form for registration of securities | 3 | SEC Filings | ||
| 12.05. | Zeo ScientifiX, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.04. | Zeo ScientifiX, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.03. | Zeo ScientifiX, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 18.02. | Zeo ScientifiX, Inc.: ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer | 335 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / February 18, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development... ► Artikel lesen | |
| 11.02. | ZEO ScientifiX, Inc.: ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community | 295 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESS Newswire / February 11, 2025 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a clinical-stage biopharmaceutical company focused on the research and development... ► Artikel lesen | |
| 13.11.24 | ZEO ScientifiX, Inc.: ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss | 294 | ACCESS Newswire | FORT LAUDERDALE, FL / ACCESSWIRE / November 13, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX), a South Florida-based clinical-stage biopharmaceutical company, announced it has partnered... ► Artikel lesen | |
| 15.10.24 | Zeo ScientifiX, Inc.: ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians | 236 | ACCESS Newswire | Events Hosted By ZEO ScientifiX Offer Providers Practical Business Tools Along With Science And Research Insights FORT LAUDERDALE, FL / ACCESSWIRE / October 15, 2024 / ZEO ScientifiX, Inc. ("ZEO" or... ► Artikel lesen | |
| 01.10.24 | Zeo ScientifiX, Inc.: ZEO ScientifiX Partners with National Provider of Healthcare Services | 252 | ACCESS Newswire | Physicians Group, LLC's Network Of Clinics And Diverse Patient Population Will Provide ZEO With Exclusive Research-Based OpportunitiesFORT LAUDERDALE, FL / ACCESSWIRE / October 1, 2024 / ZEO ScientifiX... ► Artikel lesen | |
| 24.09.24 | Zeo ScientifiX, Inc.: ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research | 317 | ACCESS Newswire | South Florida Biotech Company Seeks To Expand Its Research Program Into Phase 2 Clinical TrialsFORT LAUDERDALE, FL / ACCESSWIRE / September 24, 2024 / ZEO ScientifiX, Inc. ("ZEO" or the "Company") (OTCQB:ZEOX)... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,700 | -1,60 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 22,400 | -20,06 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| ARCELLX | 72,71 | +1,08 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| NUVALENT | 78,50 | -0,10 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| BIONTECH | 86,45 | -1,03 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| 89BIO | 8,520 | -1,27 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,605 | -6,48 % | Is Summit Therapeutics a Buy, Sell, or Hold Now? | ||
| EVOTEC | 5,846 | +0,62 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat das Kursziel für Evotec von 11,90 auf 11,20 Euro gesenkt, aber die Einstufung auf "Outperform" belassen. Die so wichtige Markterholung sei zwar... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,360 | -6,61 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| TOURMALINE BIO | 47,590 | -0,10 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 11,830 | +12,56 % | Amylyx Pharmaceuticals: Strategische Fortschritte bei seltenen Erkrankungen | ||
| MINERALYS THERAPEUTICS | 38,590 | +0,23 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| AVIDITY BIOSCIENCES | 46,360 | -0,64 % | Deep Dive Into Avidity Biosciences Stock: Analyst Perspectives (8 Ratings) | ||
| TREVI THERAPEUTICS | 9,610 | +14,13 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,750 | -3,90 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
ZEO SCIENTIFIX INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZEO SCIENTIFIX INC finden Sie auf Wallstreet Online.